Gilead Viread Virology Data Will Distinguish HIV Drug In Physician Promotions
Executive Summary
Gilead will highlight Viread virology data to distinguish the HIV treatment in physician promotions
You may also be interested in...
Bristol Reyataz Gets Broad Label Vote Despite Concerns In Drug Experienced
Bristol-Myers Squibb's protease inhibitor Reyataz is on track for a June approval with a broad label recommendation following a positive advisory committee review May 13
Bristol Reyataz Gets Broad Label Vote Despite Concerns In Drug Experienced
Bristol-Myers Squibb's protease inhibitor Reyataz is on track for a June approval with a broad label recommendation following a positive advisory committee review May 13
Roche Fuzeon Approval Presents Challenges Of Reimbursement, Supply
AIDS Drug Assistance Program coverage of Roche's antiretroviral Fuzeon could hinge upon the agent's role as either replacement or add-on therapy